Get the Stockscreener App
3.59
4.77%
-0.18
After Hours:
3.60
0.01
+0.28%
Artiva Biotherapeutics Inc stock is traded at $3.59, with a volume of 220.65K.
It is down -4.77% in the last 24 hours and up +21.69% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$3.77
Open:
$3.74
24h Volume:
220.65K
Relative Volume:
0.12
Market Cap:
$87.69M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-24.10%
1M Performance:
+21.69%
6M Performance:
+47.13%
1Y Performance:
-67.92%
1-Day Range:
$3.56
$4.00
1-Week Range:
$3.56
$4.8395
52-Week Range:
$1.47
$15.49
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
3.59 | 92.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
What risks investors should watch in Artiva Biotherapeutics Inc. stockMarket Performance Report & Daily Entry Point Alerts - newser.com
Is Artiva Biotherapeutics Inc. stock attractive for retirement portfoliosInflation Watch & Weekly Stock Breakout Alerts - newser.com
Is Artiva Biotherapeutics Inc. stock supported by strong cash flows2025 Breakouts & Breakdowns & Safe Entry Zone Identification - newser.com
Artiva Biotherapeutics Inc. stock daily chart insightsEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - The Manila Times
Artiva Biotherapeutics to Host Webcast on Initial Safety and Translational Data for AlloNK in Autoimmune Disease Treatment - Quiver Quantitative
Can Artiva Biotherapeutics Inc. stock resist sector downturnsPortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Relative strength of Artiva Biotherapeutics Inc. in sector analysis2025 Performance Recap & Free Expert Approved Momentum Trade Ideas - newser.com
Advanced analytics toolkit walkthrough for Artiva Biotherapeutics Inc.2025 Stock Rankings & Weekly Breakout Stock Alerts - newser.com
Why Artiva Biotherapeutics Inc. stock could rally in 2025Quarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Why Artiva Biotherapeutics Inc. stock is popular among millennialsWeekly Market Summary & AI Enhanced Trading Signals - newser.com
How resilient is Artiva Biotherapeutics Inc. stock in market downturnsEarnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Published on: 2025-11-03 03:05:55 - newser.com
Will Artiva Biotherapeutics Inc. stock beat EPS estimatesPortfolio Performance Report & Reliable Entry Point Trade Alerts - newser.com
Identifying reversal signals in Artiva Biotherapeutics Inc.July 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
How to escape a deep drawdown in Artiva Biotherapeutics Inc.Oil Prices & Fast Entry and Exit Trade Plans - newser.com
Artiva Biotherapeutics Inc. stock volume spike explained2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
Published on: 2025-11-02 01:36:46 - newser.com
Published on: 2025-11-01 12:39:19 - newser.com
Published on: 2025-11-01 06:37:19 - newser.com
Best Small Cap Stocks To ConsiderOctober 19th - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Why analysts remain bullish on Artiva Biotherapeutics Inc. stockBull Run & Free Weekly Watchlist of Top Performers - newser.com
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewswire
Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease - San Diego Business Journal
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):